ГАСТРОЭЗОФАГЕАЛЬНАЯ РЕФЛЮКСНАЯ БОЛЕЗНЬ И ИНФЕКЦИЯ HELICOBACTER PYLORI
Аннотация
Ассоциация между гастроэзофагеальной рефлюксной болезнью (ГЭРБ) и инфекцией Helicobacter pylori (H. pylori) является поводом для дискуссий уже в течение многих лет. Многочисленные исследования и метаанализы, проведенные к настоящему времени, продемонстрировали обратную корреляцию инфекции H. pylori (особенно CagA-положительных штаммов) с развитием осложненных форм ГЭРБ, включая пищевод Баррета и аденокарциному пищевода. Предположительно, развитие H. pylori-ассоциированного атрофического пангастрита способно оказывать протективную функцию, снижая аномальное воздействие соляной кислоты на слизистую оболочку дистального отдела пищевод. Согласно нескольким метаанализам успешная эрадикация H. pylori является фактором риска развития ГЭРБ в азиатской популяции, но не оказывает достоверного влияния у населения западных стран.
Об авторах
Д. Н. Андреев
ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А. И. Евдокимова» Минздрава России
Россия
Россия
И. В. Маев
ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А. И. Евдокимова» Минздрава России
Россия
Россия
Список литературы
1. Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И., и др. VI национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017; 2: 3-21.
2. El-Serag H., Sweet S., Winchester C., Dent J. Update on the epidemiology of gastro- oesophageal reflux disease: a systematic review. Gut 2014; 63:871-80.
3. Лазебник Л. Б., Машарова А. А., Бордин Д. С. и др. Результаты многоцентрового исследования «Эпидемиология Гастроэзофагеальной РЕфлюксной болезни в России» («МЭГРЕ»). Терапевтический архив. 2011; 1: 45-50.
4. Richter J. E., Friedenberg F. K. Gastroesophageal reflux disease. In.: Sleisenger and Fordtran’s Gastrointestinaland Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. 10th ed. 2015.
5. Mansour NM, Groth SS, Anandasabapathy S. Esophageal Adenocarcinoma: Screening, Surveillance, and Management. Annu Rev Med. 2017; 68:213-227.
6. Маев И. В., Андреев Д. Н., Кучерявый Ю. А., Щегланова М. П. Аденокарцинома пищевода: факторы риска и современные стратегии скрининга. РЖГГК. 2017; 2: 3-8.
7. Saraggi D, Fassan M, Bornschein J, Farinati F, Realdon S, Valeri N, Rugge M. From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Histol Histopathol. 2016;31(1):25-32.
8. Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North Am. 2015; 44(2):203-31
9. Hampel H, Abraham N, El-Serag H. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of internal medicine. 2005;143(3):199-211.
10. Jarosz M, Taraszewska A. Risk factors for gastroesophageal reflux disease: the role of diet. Prz Gastroenterol. 2014;9(5):297-301.
11. Body C, Christie JA. Gastrointestinal Diseases in Pregnancy: Nausea, Vomiting, Hyperemesis Gravidarum, Gastroesophageal Reflux Disease, Constipation, and Diarrhea. Gastroenterol Clin North Am. 2016;45(2):267-83.
12. Маев И. В., Андреев Д. Н., Кучерявый Ю. А. Инфекция Helicobacter pylori и экстрагастродуоденальные заболевания. Терапевтический архив. 2015; 8: 103-110.
13. Kyburz A, Müller A. Helicobacter pylori and Extragastric Diseases. Curr Top Microbiol Immunol. 2017;400:325-347.
14. Маев И. В., Самсонов А. А., Андреев Д. Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016.
15. Morgan D.R, Crowe S. E. Helicobacter pylori infection. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. - 10th ed. 2015.
16. Маев И. В., Самсонова А. А., Андреев Д. Н., Гречушников В. Б., Коровина В. Б. Клиническое значение инфекции Helicobacter pylori. Клин. мед. 2013; 8: 4-12.
17. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1):6-30
18. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38.
19. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing. Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112(5):1442-7.
20. Kandulski A, Malfertheiner P. Helicobacter pylori and gastroesophageal reflux disease. Curr Opin Gastroenterol. 2014;30(4):402-7.
21. Konturek PC, Konturek SJ, Brzozowski T. Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol. 2006;57 Suppl 3:51-65.
22. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003;326(7392):737.
23. O’Connor HJ. Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther. 1999;13(2):117-27.
24. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P, Parsonnet J. Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter. 2008;13(5):352-60.
25. Nordenstedt H, Nilsson M, Johnsen R, Lagergren J, Hveem K. Helicobacter pylori infection and gastroesophageal reflux in a population-based study (The HUNT Study). Helicobacter. 2007;12(1):16-22.
26. Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao JY. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol. 2014;12(2):239-45.
27. Chung SJ, Lim SH, Choi J, Kim D, Kim YS, Park MJ, Yim JY, Kim JS, Cho SH, Jung HC, Song IS. Helicobacter pylori Serology Inversely Correlated With the Risk and Severity of Reflux Esophagitis in Helicobacter pylori Endemic Area: A Matched Case-Control Study of 5,616 Health Check-Up Koreans. J Neurogastroenterol Motil. 2011;17(3):267-73.
28. Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, Sakaguchi Y, Nakayama C, Konno-Shimizu M, Matsuda R, Mochizuki S, Asada-Hirayama I, Tsuji Y, Kodashima S, Ono S, Niimi K, Mitsushima T, Koike K. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013;8(7): e69891.
29. Lupu VV, Ignat A, Ciubotariu G, Ciubară A, Moscalu M, Burlea M. Helicobacter pylori infection and gastroesophageal reflux in children. Dis Esophagus. 2016;29(8):1007-1012.
30. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007;5(12):1413-7, 1417.e1-2.
31. Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, El-Serag HB. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012;17(3):163-75.
32. Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, Shao L, Zou DH, Yu XM, Mao WM. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013;19(36):6098-107.
33. Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014;27(7):645-53.
34. Kamada T, Haruma K, Kawaguchi H, Yoshihara M, Sumii K, Kajiyama G. The association between antral G and D cells and mucosal inflammation, atrophy, and Helicobacter pylori infection in subjects with normal mucosa, chronic gastritis, and duodenal ulcer.Am J Gastroenterol. 1998;93(5):748-52.
35. Ghoshal UC, Chourasia D. Gastroesophageal Reflux Disease and Helicobacter pylori: What May Be the Relationship? J Neurogastroenterol Motil. 2010;16(3):243-50.
36. Wang F, Xia P, Wu F, Wang D, Wang W, Ward T, Liu Y, Aikhionbare F, Guo Z, Powell M, Liu B, Bi F, Shaw A, Zhu Z, Elmoselhi A, Fan D, Cover TL, Ding X, Yao X. Helicobacter pylori VacA disrupts apical membrane-cytoskeletal interactions in gastric parietal cells. J Biol Chem. 2008; 283(39):26714-25.
37. Helmer KS, West SD, Vilela R, Chang L, Cui Y, Kone BC, Mercer DW. Lipopolysaccharide-induced changes in rat gastric H/K-ATPase expression. Ann Surg. 2004;239(4):501-9.
38. Artiko VM, Chebib HY, Ugljesic MB, Petrovic MN, Obradovic VB. Relationship between enterogastric reflux estimated by scintigraphy and the presence of Helicobacter pylori. Hepatogastroenterology. 1999;46(26):1234-7.
39. Manifold DK, Anggiansah A, Rowe I, Sanderson JD, Chinyama CN, Owen WJ. Gastro-oesophageal reflux and duodenogastric reflux before and after eradication in Helicobacter pylori gastritis. Eur J Gastroenterol Hepatol. 2001;13(5):535-9.
40. Gall A, Fero J, McCoy C, Claywell BC, Sanchez CA, Blount PL, Li X, Vaughan TL, Matsen FA, Reid BJ, Salama NR. Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett’s Esophagus Cohort. PLoS One. 2015;10(6): e0129055.
41. Fallone CA, Barkun AN, Friedman G, Mayrand S, Loo V, Beech R, Best L, Joseph L. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol. 2000 Apr;95(4):914-20.
42. Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: new threats of the old friend. Ann Clin Microbiol Antimicrob. 2005;4:1.
43. Tanaka I, Tatsumi Y, Kodama T, Kato K, Fujita S, Mitsufuji S, Kashima K. Effect of Helicobacter pylori eradication on gastroesophageal function. J Gastroenterol Hepatol. 2004;19(3):251-7.
44. Hamada H, Haruma K, Mihara M, Kamada T, Yoshihara M, Sumii K, Kajiyama G, Kawanishi M. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther. 2000;14(6):729-35.
45. Nakajima S, Hattori T. Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy. Helicobacter. 2003;8(4):279-93.
46. Sakata H, Fujimoto K. Barrett’s esophagus and Helicobacter pylori. Nihon Rinsho. 2005;63(8):1383-6.
47. Hong SJ, Kim SW. Helicobacter pylori Infection in Gastroesophageal Reflux Disease in the Asian Countries. Gastroenterol Res Pract. 2015;2015:985249.
48. Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25(10):1195-205.
49. Wang XT, Zhang M, Chen CY, Lyu B. Helicobacter pylori eradication and gastroesophageal reflux disease: a Meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55(9):710-6.
50. Yaghoobi M., Farrokhyar F., Yuan Y., Hunt R. H. Is there an increased risk of GERD after Helicobacter pylori eradication: a meta-analysis. The American Journal of Gastroenterology. 2010;105(5):1007-1013.
51. Qian B., Ma S., Shang L., Qian J., Zhang G. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. Helicobacter. 2011;16(4):255-265.
52. Saad A. M., Choudhary A., Bechtold M. L. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scandinavian Journal of Gastroenterology. 2012;47(2):129-135.
53. Iijima K, Koike T, Shimosegawa T. Reflux esophagitis triggered after Helicobacter pylori eradication: a noteworthy demerit of eradication therapy among the Japanese? Front Microbiol. 2015;6:566.
54. Rokkas T, Ladas SD, Triantafyllou K, Liatsos C, Petridou E, Papatheodorou G, Karameris A, Raptis SA. The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. Am J Med. 2001;110(9):703-7.
55. Чотчаева А. Р., Пасечников Д. В., Пасечников В. Д. Определение факторов риска и предикторов развитие ГЭРБ после эрадикации бактерии H. pylori у больных язвенной болезнью. РЖГГК. 2008; 5 S 32: 43.
56. Malfertheiner P., Megraud F., O’Morain C. et al; European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012; 61 (7): 646-664.
57. Kuipers EJ, Uyterlinde AM, Peña AS, Hazenberg HJ, Bloemena E, Lindeman J, Klinkenberg-Knol EC, Meuwissen SG. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90(9):1401-6.
58. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HP, Dent J, Zeitoun P, Havu N, Lamm M, Walan A. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004; 53(1):12-20.
59. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, Luckers AE, Klinkenberg-Knol EC, Festen HP, Viergever PP, Lindeman J, Meuwissen SG. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 2000;46(5):615-21.
60. Андреев Д. Н., Дичева Д. Т., Маев И. В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017; 2: 76-83.
61. Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract. 2016;2016:9086581.
62. Desta ZX, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C 19 genetic polymorphism. Clin. Pharmacokinet. 2002; 41(12): 913-958.
63. Maev I. V., Andreev D. N., Kucheryavyi Yu.A., Dicheva D. T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014; 30: 134-140.
64. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C 19: functional and clinical implications of a new variant CYP2C 19*17. Br J Clin Pharmacol. 2010;69(3):222-30.
65. Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C 19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029-36.
66. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C 19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101(7):1467-75. DOI: 10.1111/j.1572-0241.2006.00717.x
67. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K. CYP2C 19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18(6):721-7.
68. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C 19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013;8: e62162.
69. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414-25.
70. Denisenko NP, Sychev DA, Sizova ZhM, Grachev AV, Velikolug KA. High frequency of CYP2C 19 ultrarapid metabolizers in Russian patients with peptic ulcer. Eksp Klin Gastroenterol. 2015;(6):11-5.
71. Андреев Д. Н., Дичева Д. Т., Лебедева Е. Г., Парцваниа-Виноградова Е. В. Фармакологические основы применения ингибиторов протонной помп. Фарматека. 2014; 14: 62-69.
72. Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56(2):57-70.
73. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438-46.
74. Pantoflickova D, Dorta G, Jornod P, Ravie M., Blum A. Identification of the characteristics influencing the degree of antisecretory activity of PPIs [abstract]. Gastroenterology. 2000;118: A5895.
75. Tejura B, Boyce M, Warrington S. Rabeprazole is more potent than esomeprazole in control of gastric pH in healthy volunteers [abstract]. Ninth United European Gastroenterology Week Meeting, Amsterdam, The Netherlands. October 2001.
76. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19-31.
77. Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001 Jun;6(2):125-9.
78. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010 Mar 14;16(10):1279-84.
79. Skoczylas T., Sarosiek I., Sostarich S. et al. Signicant enhancement of gastric mucin content after rabeprazole administration: its potential clinical signicance in acid-related disorders // Dig. Dis. Sci. 2003. Vol. 48. Р. 322-328.
80. Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, Shimamura Y, Morishita N. Pharmacokinetic properties of E 3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32(9):466-73.
Рецензия
Для цитирования:
Андреев Д.Н., Маев И.В. ГАСТРОЭЗОФАГЕАЛЬНАЯ РЕФЛЮКСНАЯ БОЛЕЗНЬ И ИНФЕКЦИЯ HELICOBACTER PYLORI. Экспериментальная и клиническая гастроэнтерология. 2017;(6):105-111.
For citation:
Andreev D.N., Maev I.V. GASTROESOPHAGEAL REFL UX DISEASE AND INFECTION HELICOBACTER PYLORI. Experimental and Clinical Gastroenterology. 2017;(6):105-111. (In Russ.)
Просмотров:
345
Послать статью по эл. почте 